Experiencing these effects does not necessarily mean that treatment is unsuitable
In the ATTAIN-2 trial in patients with diabetes, discontinuation rates due to adverse events were 6.1-9.9% for orforglipron versus 4.1% for placebo
Lancet Gastroenterol Hepatol 2(12):890899 Halim MA, Degerblad M, Sundbom M, Karlbom U, Holst JJ, Webb D-L et al (2018) Glucagon-like peptide-1 inhibits prandial gastrointestinal motility through myenteric neuronal mechanisms in humans
H., Maljevic, Snezana, Quaife-Ryan, Gregory A., Hudson, James E., Porrello, Enzo R., White, Melanie Y., Cordwell, Stuart J., Fraser, John F., Petrou, Steven, Reichelt, Melissa E
Sermorelin/Ipamorelin is a peptide combination used to support the bodys natural release of growth hormone through complementary signaling pathways rather than direct HGH replacement